Conv. Plasma
Nigella Sativa
Peg.. Lambda

All cannabidiol studies
Meta analysis
Home COVID-19 treatment researchCannabidiolCannabidiol (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization -557% Improvement Relative Risk Recovery time -33% Cannabidiol  Crippa et al.  LATE TREATMENT  DB RCT Is late treatment with cannabidiol beneficial for COVID-19? Double-blind RCT 91 patients in Brazil (July - October 2020) Higher hospitalization (p=0.25) and slower recovery (p=0.21), not sig. Crippa et al., Cannabis and Cannabinoi.., Oct 2021 Favors cannabidiol Favors control

Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Crippa et al., Cannabis and Cannabinoid Research, doi:10.1089/can.2021.0093
Oct 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 105 patients recruited in an ER in Brazil, 49 treated with CBD, showing no significant differences with treatment. 300mg CBD for 14 days.
For discussion see
risk of hospitalization, 557.1% higher, RR 6.57, p = 0.25, treatment 3 of 49 (6.1%), control 0 of 42 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
recovery time, 33.3% higher, relative time 1.33, p = 0.20, treatment 49, control 42.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Crippa et al., 7 Oct 2021, Double Blind Randomized Controlled Trial, placebo-controlled, Brazil, peer-reviewed, 32 authors, study period 7 July, 2020 - 16 October, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCannabidiolAll
Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
José Alexandre S Crippa, Julia Cozar Pacheco, Antonio W Zuardi, Francisco S Guimarães, Alline Cristina Campos, Flávia De Lima Osório, Sonia Regina Loureiro, Rafael G Dos Santos, José Diogo S Souza, Juliana Mayumi Ushirohira, Rafael Rinaldi Ferreira, Karla Cristinne Mancini Costa, Davi Silveira Scomparin, Franciele Franco Scarante, Isabela Pires-Dos-Santos, Raphael Mechoulam, Flávio Kapczinski, Benedito A L Fonseca, Danillo L A Esposito, Afonso Dinis Costa Passos, Amaury Lelis Dal Fabbro, Fernando Bellissimo-Rodrigues, Eurico Arruda, Sandro Scarpelini, Maristela Haddad Andraus, Julio Cesar Nather Junior, Danilo Tadao Wada, Marcel Koenigkam-Santos, Antonio Carlos Santos, Geraldo Busatto Filho, Jaime E C Hallak
Cannabis and Cannabinoid Research, doi:10.1089/can.2021.0093
Importance: Owing to its anti-inflammatory properties and antiviral ''in vitro'' effect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), cannabidiol (CBD) has been proposed as a potential treatment for coronavirus disease 2019 (COVID-19). Objective: To investigate the safety and efficacy of CBD for treating patients with mild to moderate COVID-19. Design: Randomized, parallel-group, double-blind, placebo-controlled clinical trial conducted between July 7 and October 16, 2020, in two sites in Brazil. Setting: Patients were recruited in an emergency room. Participants: Block randomized patients (1:1 allocation ratio-by a researcher not directly involved in data collection) with mild and moderate COVID-19 living in Ribeira ˜o Preto, Brazil, seeking medical consultation, and those who voluntarily agreed to participate in the study. Interventions: Patients received 300 mg of CBD or placebo added to standard symptomatic care during 14 days. Main Outcome and Measure: The primary outcome was reduction or prevention of the deterioration in clinical status from mild/moderate to severe/critical measured with the COVID-19 Scale or the natural course of the resolution of typical clinical symptoms. Primary study outcome was assessed on days 14, 21, and 28 after enrollment. Results: A total of 321 patients were recruited and assessed for eligibility, and 105 were randomly allocated either in CBD (n = 49) or in placebo (n = 42) group. Ninety-one participants were included in the analysis of efficacy. There were no baseline between-group differences regarding disease severity (v 2 = 0.025, p = 0.988) and median time to symptom resolution (12 days [95% confidence interval, CI, 6.5-17.5] in the CBD group, 9 days [95% CI,
Anil, Shalev, Vinayaka, Cannabis compounds exhibit antiinflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages, Sci Rep
Bergamaschi, Queiroz, Chagas, Cannabidiol reduces the anxiety induced by simulated public speaking in treatmentnaı ¨ve social phobia patients, Neuropsychopharmacology
Biali, Broers, Besson, Cannabinoids and COVID-19, Med Cannabis Cannabinoids
Byrareddy, Mohan, SARS-CoV2 induced respiratory distress: can cannabinoids be added to anti-viral therapies to reduce lung inflammation?, Brain Behav Immun
Campos, Brant, Miranda, Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria, Neuroscience
Campos, Ferreira, Guimara, Fs, Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors, J Psychiatr Res
Campos, Ortega, Palazuelos, The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system, Int J Neuropsychopharmacol
China, National Health Commission of the People's Republic of China
Crippa, Guimara ˜es, Campos, Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age, Front Immunol
Crippa, Pacheco, Zuardi, Guimara ˜es, Campos et al., for the Cannabidiol for COVID-19 Patients (CANDIDATE) Trial Investigators (2021) Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial, Cannabis and Cannabinoid Research X:X
Dong, Tang, Wang, The role of imaging in the detection and management of COVID-19: a review, IEEE Rev Biomed Eng
Dos-Santos-Pereira, ˜es, Bel, Cannabidiol prevents LPS-induced microglial inflammation by inhibiting ROS/ NF-jB-dependent signaling and glucose consumption, Glia
Esposito, Pesce, Seguella, The potential of cannabidiol in the COVID-19 pandemic, Br J Pharmacol
Fu, Kong, Wang, The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: a retrospective study in Suzhou China, Thromb Res
Jimeno, Ventura, Castellano, Prognostic implications of neutrophil-lymphocyte ratio in COVID-19, Eur J Clin Invest
Khodadadi, Salles, ´l, Jarrahi, Cannabidiol modulates cytokine storm in acute respiratory distress syndrome induced by simulated viral infection using synthetic RNA, Cannabis Cannabinoid Res
Long, Zeng, Zhang, Short-term outcomes of COVID-19 and risk factors for progression, Eur Respir J
Mabou Tagne, Pacchetti, Sodergren, Cannabidiol for viral diseases: hype or hope? Cannabis Cannabinoid, Res
Malinowska, Baranowska-Kuczko, Kicman, Opportunities, challenges and pitfalls of using cannabidiol as an adjuvant drug in COVID-19, Int J Mol Sci
Masataka, Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders, Front Psychol
Mecha, Feliu, ˜igo, Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors, Neurobiol Dis
Moreno, Desousa, Souza, Factor structure, reliability, and item parameters of the Brazilian-Portuguese version of the GAD-7 questionnaire, Temas Psicol
Oso, Vilela Mendes, Crippa, Study of the discriminative validity of the PHQ-9 and PHQ-2 in a sample of Brazilian women in the context of primary health care, Perspect Psychiatr Care
Pacheco, Souza, Hallak, Cannabidiol as a treatment for mental health outcomes among health care workers during the coronavirus disease pandemic, J Clin Psychopharmacol
Raj, Park, Cho, Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches, Int J Biol Macromol
Richardson, Hirsch, Narasimhan, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA
Salles, ´l, Khodadadi, Jarrahi, Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome, J Cell Mol Med
Sonego, Prado, Vale, Cannabidiol prevents haloperidolinduced vacuos chewing movements and inflammatory changes in mice via PPARc receptors, Brain Behav Immun
Stamps, Bartoshuk, Heilman, A brief olfactory test for Alzheimer's disease, J Neurol Sci
Suryavanshi, Kovalchuk, Kovalchuk, Cannabinoids as key regulators of inflammasome signaling: a current perspective, Front Immunol
Vuolo, Abreu, Michels, Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma, Eur J Pharmacol
Zanelati, Biojone, Moreira, Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT 1A receptors, Br J Pharmacol
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop